DHN198
Phase 1- Indications
- Solid tumors, Cancer with immunosuppressive inflammation
Company intelligence / Profile preview
Landmark BioVentures AG
Basel, Basel-Stadt, Switzerlandlandmarkbioventures.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
LBV operates a diversified model with seven companies developing ten first-in-class therapeutics in oncology, rare disease, immunology, and metabolic disease. No specific clinical results disclosed publicly.
- Therapeutic areas
- ImmunologyOncologyRare Diseases
- Modalities
- Small moleculesBiologics
- Industry
- Investors
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Landmark BioVentures AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Landmark BioVentures AG.